Ganglion Plexus Ablation in Persistent Atrial Fibrillation

Launched by NING ZHOU · Dec 12, 2023

Keywords

ClinConnect Summary

This clinical trial is studying a treatment for a heart condition called persistent atrial fibrillation, which is a type of irregular heartbeat that can lead to serious complications. Specifically, the trial will explore how well a procedure called ganglionated plexus ablation works when combined with another treatment called radiofrequency ablation. The goal is to see if this combined approach can help patients feel better in the long run and is safe to use.

To participate in this study, you need to be between 18 and 80 years old and have been diagnosed with persistent atrial fibrillation. You should also be scheduled for a catheter ablation procedure, which is a common treatment for this condition. However, there are some health conditions that would prevent you from joining, such as having certain heart problems, serious infections, or recent heart surgery. If you decide to take part, you will need to give your consent and can expect close monitoring during and after the treatment to ensure your safety and track your progress. This trial is not yet recruiting participants, but it could offer new insights into better treatments for atrial fibrillation in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age between 18 and 80 years, regardless of gender.
• • Patients confirmed by electrocardiogram or clinically diagnosed with persistent atrial fibrillation.
• • Individuals scheduled to undergo atrial fibrillation catheter ablation.
• • Willing to participate in the study and voluntarily sign the informed consent form.
• Exclusion Criteria:
• • Patients with a history of prior atrial fibrillation ablation surgery.
• • Left ventricular ejection fraction (LVEF) less than 35%.
• • Left atrial anterior-posterior diameter greater than 50mm on echocardiography.
• • Presence of contraindications for atrial fibrillation ablation, such as the presence of clear thrombus in the left atrium detected preoperatively.
• • Patients with second-degree (Type II) or third-degree atrioventricular block.
• • Individuals with significant congenital heart defects (such as atrial septal defects or severe pulmonary vein stenosis, excluding unclosed foramen ovale).
• • Patients with implanted artificial valves.
• • Diagnosed with hypertrophic cardiomyopathy, chronic obstructive pulmonary disease, or myxoma.
• • Untreated or uncontrolled hyperthyroidism or hypothyroidism.
• • Patients with active systemic infections.
• • Individuals with a significant bleeding tendency or those undergoing active blood dialysis due to renal failure.
• • Patients who have experienced myocardial infarction within the last 3 months or undergone any cardiac intervention/open-heart surgery.
• • Presence of clear contraindications for interventional procedures, as determined by the investigator.
• • Pregnant or lactating women, or those planning pregnancy during the study period.
• • Participation in other drug or medical device clinical trials within the last 3 months.
• • Patients deemed unsuitable for participation in this clinical trial by the investigator.